uniQure (NASDAQ:QURE) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of uniQure (NASDAQ:QURE) from a sell rating to a hold rating in a research report released on Sunday.

Several other analysts also recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $53.00 target price on shares of uniQure in a report on Tuesday, November 11th. Cantor Fitzgerald lifted their price objective on uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, September 25th. William Blair reiterated a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Leerink Partners cut their target price on uniQure from $68.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday, November 10th. Finally, UBS Group set a $95.00 price target on uniQure in a research note on Thursday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $64.42.

uniQure Trading Down 0.5%

NASDAQ:QURE opened at $27.49 on Friday. uniQure has a 12-month low of $5.89 and a 12-month high of $71.50. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The stock’s 50 day simple moving average is $45.78 and its 200-day simple moving average is $25.90. The firm has a market cap of $1.71 billion, a P/E ratio of -7.01 and a beta of 0.59.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. Equities analysts anticipate that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling at uniQure

In other uniQure news, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the completion of the transaction, the chief financial officer owned 217,730 shares in the company, valued at approximately $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jack Kaye sold 38,810 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the completion of the sale, the director owned 20,439 shares in the company, valued at $620,119.26. This represents a 65.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 314,560 shares of company stock valued at $12,362,568. Insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Hedge funds have recently bought and sold shares of the stock. Private Trust Co. NA acquired a new position in uniQure during the third quarter worth about $28,000. Jones Financial Companies Lllp boosted its position in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC bought a new position in shares of uniQure during the 3rd quarter valued at about $50,000. Tower Research Capital LLC TRC grew its stake in shares of uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of uniQure in the 2nd quarter worth approximately $117,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.